

# Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



11<sup>th</sup> February, 2019

To,  
Corporate Relation Department  
BSE Ltd  
1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

National Stock Exchange of India  
Limited  
“Exchange Plaza”, 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051

Scrip Code: 532637

Symbol: MANGALAM

**Sub: Outcome of the Board Meeting held on 11<sup>th</sup> February, 2019**

Dear Sir,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that, the meeting of Board of Directors was held today i.e. Monday, 11<sup>th</sup> February, 2019 at 12.00 P.M at the time scheduled for the meeting at the registered office of the company, where in the following business was inter-alia transacted:

1. Approved the Un-Audited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2018 along with the Limited Review Report on the results pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015;
2. Other Business transacted with permission of chair.

The Board Meeting concluded at 3.20 P.M.

You are requested to take the same on your records.

Thanking You,

Yours faithfully,  
For Mangalam Drugs & Organics Ltd

Nikita Bavishi  
Company Secretary



**Un-Audited Financial Results for the Quarter & Nine Months Ended 31st December 2018 approved and taken on record by the Board at their meeting dated 11th February, 2019**

Sr.No	Particulars	Quarter Ended			Nine Months Ended		Rs. in Lacs
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A) Part-1 Statement of Un-Audited Financial Results for the Quarter and Nine Months Ended December 31, 2018</b>							
1	Revenue from Operations	4,858.28	7,190.07	7,390.71	17,949.06	21,218.46	27,937.96
2	Other Income	4.54	3.84	64.34	11.15	72.44	82.70
3	Total Revenue(1+2)	<b>4,862.82</b>	<b>7,193.91</b>	<b>7,455.05</b>	<b>17,960.21</b>	<b>21,290.90</b>	<b>28,020.66</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	3,951.23	5,471.41	5,590.59	13,133.21	14,003.39	18,047.91
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in Inventories, Finished Goods and Stock-in-trade	(784.01)	(658.31)	(1,005.02)	(1,357.20)	(1,730.49)	(1,711.73)
	(d) Employee Benefits Expense	636.77	642.98	563.03	1,933.65	1,701.25	2,298.37
	(e) Finance Costs	229.53	174.43	249.85	612.11	835.08	1,178.00
	(f) Depreciation	183.49	181.47	147.65	543.15	399.04	656.82
	(g) Other Expenses	1,153.61	1,179.20	980.79	3,297.66	3,508.60	4,616.57
	<b>Total Expenses</b>	<b>5,370.62</b>	<b>6,991.18</b>	<b>6,526.89</b>	<b>18,162.57</b>	<b>18,716.87</b>	<b>25,085.94</b>
5	<b>Profit / (Loss) before exceptional &amp; extraordinary items and tax(3-4)</b>	<b>(507.80)</b>	<b>202.73</b>	<b>928.16</b>	<b>(202.36)</b>	<b>2,574.03</b>	<b>2,934.72</b>
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	<b>Profit/(Loss) before extraordinary items and tax (5-6)</b>	<b>(507.80)</b>	<b>202.73</b>	<b>928.16</b>	<b>(202.36)</b>	<b>2,574.03</b>	<b>2,934.72</b>
8	<b>Extraordinary Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
9	<b>Profit(+)/Loss (-) before tax(7-8)</b>	<b>(507.80)</b>	<b>202.73</b>	<b>928.16</b>	<b>(202.36)</b>	<b>2,574.03</b>	<b>2,934.72</b>
10	Tax Expenses	(65.82)	29.93	330.23	0.00	890.61	945.76
11	<b>Net Profit(+)/Loss(-) after Tax (9-10)</b>	<b>(441.98)</b>	<b>172.80</b>	<b>597.93</b>	<b>(202.36)</b>	<b>1,683.42</b>	<b>1,988.96</b>
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.41	0.43	62.05	1.26	71.04	36.32
13	<b>Total Comprehensive Income</b>	<b>(441.57)</b>	<b>173.23</b>	<b>659.98</b>	<b>(201.10)</b>	<b>1,754.46</b>	<b>2,025.28</b>
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity						8,935.43
16	<b>Earnings Per Share (EPS) (of Rs 10/-each)not annualised):</b>						
	(a) Basic	(2.79)	1.09	3.78	(1.28)	10.64	12.57
	(b) Diluted	(2.79)	1.09	3.78	(1.28)	10.64	12.57

**Notes :**

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on February 11, 2019. The Statutory Auditors have carried out a limited review of the results.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments"
- The company has incurred loss in this quarter due to certain unforeseen circumstances & the major reason being delay in finalisation of tenders for malaria drugs by international regulatory. However we are confident of improved results in subsequent quarters once these procurements are streamlined by them shortly
- Earlier period figures have been regrouped/ rearranged wherever necessary

Place: Mumbai  
Date: 11th February, 2019

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)  
Chairman & Managing Director  
(DIN:01240086)



**Independent Auditors' review report on the review of Interim Financial results**  
**for the Quarter and Nine month ended December 2018.**

To,

**The Board of Directors of,**  
**Mangalam Drugs & Organics Limited.**

1. We have reviewed the accompanying statement of unaudited financial results of **Mangalam Drugs & Organics Limited**("the Company") for the quarter and nine months ended 31<sup>st</sup> December, 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



**BRANCHES :**


**NAVI MUMBAI :** 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478  
**DELHI :** 505, Nirmai Tower, 26, Barakhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards as notified under the Companies ( Indian Accounting Standards) Rules,2015 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai  
Date: February 11<sup>th</sup>, 2019

For Batliboi&Purohit  
Chartered Accountants  
FRN: 101048W



Parag Hangekar  
Partner  
M.No. 110096

